Pfizer — the strategy behind it | Stratrix

Company profile

Industry: Pharmaceutical Preparations
Listed: NYSE: PFE
Incorporated: DE
Headquarters: New York, NY
Fiscal year end: Dec 31

Financials

FY2025

Revenue: $62.6B
Net income: $7.77B
Total assets: $208.2B

Pfizer — reported revenue, net income and total assets by fiscal year, from SEC filings
Fiscal year	Revenue	Net income	Total assets
FY2025	$62.6B	$7.77B	$208.2B
FY2024	$63.6B	$8.03B	$213.4B
FY2023	$50.9B	$2.12B	$226.5B
FY2022	$91.8B	$31.4B	$197.2B
FY2021	$73.6B	$22.0B	$181.5B
FY2020	$41.7B	$9.16B	$154.2B

Reported fiscal years from SEC filings (10-K) — SEC EDGAR ↗. Stratrix is a strategy publication, not a real-time financial data service.

The analyses

The Adjacency Expansion · Growth & Portfolio

Pfizer Spent Two Decades Buying Its Way Out of Its Core. Then It Bought Its Way Back.

Pfizer's animal health, consumer health, and generics arms were sold as diversification. They came attached to pharma megadeals as cargo — and by 2020 Pfizer had spun off all of it to become, by its own 10-K's words, 'a more focused' drugmaker again.

The Adjacency Expansion · Growth & Portfolio

Pfizer Made $57 Billion From COVID. Then It Spent $43 Billion to Replace Itself.

In 2022 COVID products were 57% of Pfizer's revenue. By 2023 they had collapsed 78%, total sales fell 42%, and EPS dropped 93% to $0.37. The acquisition spree that followed wasn't strategy. It was a company outrunning its own cliff.

The Cannibalization Choice · Decision Forks

Pfizer Shed Zoetis, Consumer, Then Upjohn — a Tax-Free Escape Driven by EPS Math

Over a decade Pfizer shed Zoetis, its consumer business, and finally Upjohn — $2.2B raised here, an $8.1B gain there. The story was 'focus on innovation.' The real driver was the EPS math, and a tax-free escape from a declining asset it could not sell clean.

The Bet · Decision Forks

Pfizer Locked In $5.97 Billion of Vaccine Orders Before Shipping a Single Dose

Pfizer is celebrated for taking $2 billion of pure private risk and turning it into a $100 billion year. But it locked in $5.97 billion of guaranteed orders before a single dose shipped — and then watched the windfall fall 42% in twelve months.